Nkere U U, Whawell S A, Thompson E M, Thompson J N, Taylor K M
Royal Postgraduate Medical School, Hammersmith Hospital, London, England.
J Thorac Cardiovasc Surg. 1993 Aug;106(2):339-45.
The presence of pericardial adhesions at resternotomy not only increases the operation time but also increases the risk of serious damage to the heart, great vessels, and extracardiac grafts. The reported prevalence of damage is 2% to 6%. The fibrinolytic activity of pericardial tissue may be a crucial factor in determining the extent of adhesion formation following primary operation. Ten patients undergoing cardiac operations were studied to assess the plasminogen activating activity of homogenates of pericardial tissue samples. Samples were taken at three times during the operation and the plasminogen activating activity was measured by means of a standard fibrin plate technique. Tissue-type plasminogen activator, urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and plasminogen activator inhibitor-2 were also measured by means of enzyme-linked immunosorbent assays. Compared with its initial levels (median 2.06 IU/cm2, range 1.28 to 6.48 IU/cm2), the plasminogen activating activity of pericardial biopsy tissue was significantly reduced at 75 minutes (median 0.64 IU/cm2, range 0.12 to 2.44 IU/cm2, p < 0.01) and at 135 minutes (median 1.45 IU/cm2, range 0.12 to 4.39 IU/cm2, p < 0.05). The major plasminogen activator present was tissue-type plasminogen activator. Compared with its initial levels (median 2.34 ng/ml, range 1.03 to 6.42 ng/ml), subsequent tissue-type plasminogen activator values were also significantly reduced at 75 minutes (median 0.83 ng/ml, range 0.75 to 5.13 ng/ml, p < 0.005) and at 135 minutes (median 1.24 ng/ml, range 0.75 to 6.67 ng/ml, p < 0.05). Low levels of urokinase-type plasminogen activator were found in 5 of 10 patients. However, neither plasminogen activator inhibitor-1 nor plasminogen activator inhibitor-2 was detected. Examination with a light microscope showed both increasing pericardial mesothelial damage and increasing features of acute inflammatory changes with time. This study shows that plasminogen activating activity is present in pericardial tissue and that tissue-type plasminogen activator is the major plasminogen activator. The observed inflammatory changes and concomitant damage to the pericardial mesothelium, and the significant reductions in pericardial tissue-type plasminogen activator and plasminogen activating activity seen during cardiac operations, may be important factors contributing to the early development of pericardial adhesions.
胸骨切开术时心包粘连的存在不仅会增加手术时间,还会增加心脏、大血管和心外移植物受到严重损伤的风险。报道的损伤发生率为2%至6%。心包组织的纤溶活性可能是决定初次手术后粘连形成程度的关键因素。对10例接受心脏手术的患者进行研究,以评估心包组织样本匀浆的纤溶酶原激活活性。在手术过程中的三个时间点采集样本,并通过标准纤维蛋白平板技术测量纤溶酶原激活活性。还通过酶联免疫吸附测定法测量组织型纤溶酶原激活剂、尿激酶型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1和纤溶酶原激活剂抑制剂-2。与初始水平(中位数2.06 IU/cm²,范围1.28至6.48 IU/cm²)相比,心包活检组织的纤溶酶原激活活性在75分钟时显著降低(中位数0.64 IU/cm²,范围0.12至2.44 IU/cm²,p < 0.01),在135分钟时也显著降低(中位数1.45 IU/cm²,范围0.12至4.39 IU/cm²,p < 0.05)。存在的主要纤溶酶原激活剂是组织型纤溶酶原激活剂。与初始水平(中位数2.34 ng/ml,范围1.03至6.42 ng/ml)相比,随后的组织型纤溶酶原激活剂值在75分钟时也显著降低(中位数0.83 ng/ml,范围0.75至5.13 ng/ml,p < 0.005),在135分钟时也显著降低(中位数1.24 ng/ml,范围0.75至6.67 ng/ml,p < 0.05)。10例患者中有5例发现尿激酶型纤溶酶原激活剂水平较低。然而,未检测到纤溶酶原激活剂抑制剂-1和纤溶酶原激活剂抑制剂-2。光学显微镜检查显示,随着时间的推移,心包间皮损伤增加,急性炎症变化特征也增加。本研究表明,心包组织中存在纤溶酶原激活活性,且组织型纤溶酶原激活剂是主要的纤溶酶原激活剂。观察到的炎症变化和心包间皮的伴随损伤,以及心脏手术期间心包组织型纤溶酶原激活剂和纤溶酶原激活活性的显著降低,可能是导致心包粘连早期形成的重要因素。